A study to find out the best length of time between ocrelizumab doses for patients with relapsing remitting multiple sclerosis using a trial design with multiple groups and multiple stages

View at publisher Summarise with VIRAT
Authors: . REFINE-MS Team, Olga Ciccarelli
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Statistical Methods in Clinical Trials Chronic Lymphocytic Leukemia Research

Publication details

Journal / source
http://isrctn.com/
Publication date
26 March 2026
Language
EN